Met Life Investment Management, LLC Apellis Pharmaceuticals, Inc. Transaction History
Met Life Investment Management, LLC
- $18.1 Billion
- Q1 2025
A detailed history of Met Life Investment Management, LLC transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 6,586 shares of APLS stock, worth $125,134. This represents 0.0% of its overall portfolio holdings.
Number of Shares
6,586
Previous 6,436
2.33%
Holding current value
$125,134
Previous $205,000
29.76%
% of portfolio
0.0%
Previous 0.0%
Shares
60 transactions
Others Institutions Holding APLS
# of Institutions
286Shares Held
124MCall Options Held
921KPut Options Held
761K-
Wellington Management Group LLP Boston, MA12.3MShares$234 Million0.05% of portfolio
-
Avoro Capital Advisors LLC New York, NY12.2MShares$232 Million4.32% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.9MShares$226 Million20.45% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$192 Million0.0% of portfolio
-
Morgan Stanley New York, NY9.63MShares$183 Million0.02% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $2.09B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...